Methods of treatment using genetically modified autologous T cell immunotherapy

A technology of cells, cell populations, applied in the therapeutic area of ​​immunotherapy using genetically modified autologous T cells that can address the high unmet need for clinical benefit to patients

Pending Publication Date: 2022-06-03
派克特制药公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, despite these successes with immunotherapy, a significant proportion of treated patients with solid tumors do not respond, representing a high unmet need for patients deriving clinical benefit from novel immunotherapy approaches

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treatment using genetically modified autologous T cell immunotherapy
  • Methods of treatment using genetically modified autologous T cell immunotherapy
  • Methods of treatment using genetically modified autologous T cell immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0279] Example 1 Neotcr product

[0280] Antigen -specific target T cell kill. The treatment of mutant -targeted, personalized, over -success T cell receptors (NeoTCR products) is an immunotherapy mode, which aims to release the ability of specific identification and killing the cells of the immune system. NeoTCR cells are transformed to express Neo12 TCR (a representative new table), which is produced by NEO12 specific CD8 T cells separated from the blood of patients with melanoma, and tumor cells that are homologous or non -matching tumor cells with homologous or non -matching tumor cells Cultivate a few days to collect delay live micro -surgical images. Use delay live body micro -ingrains (0, 1 and 2 days; see figure 1 ) The representative image obtained shows that NeoTCR-T cells trained by target T cells that express the same-origin NEO12 peptide-HLA have strong antigen-specific cytotoxic activity and proliferation capabilities (right column) Target T cells do not have antigen...

Embodiment 2

[0291] Example 2 and multi -TCR Neotcr products

[0292] In certain embodiments, each Neotcr product contains a single NeoTCR, which is transformed by a precision genome to CD4+and CD8+T cells. In view of the design of NeoTCR products, NeoTCR with short -term mutation, NEOTCR products with only one (1) NeoTCR may be sufficient and effective in treating proliferative diseases (such as cancer).

[0293] The number of NeoTCR in Neotcr products does not perform the limit. Instead, the number of NeoTCR included in NeoTCR products is based on the following number of Neotcr: 1) the number of NeoTCR based on patient tumors and blood samples, or 2) hopes to have multiple NeoTCR in given products.

[0294] In some embodiments, Neotcr products include a single Neotcr. NeoTCR products include single (1) Neotcr, which is made by screening the neotcr in the patient's tumor and blood samples and selected a single (1) species Neotcr to be transformed into NEOTCR products to manufacture. In some e...

Embodiment 3

[0316] Example 3 Neotcr product combination therapy

[0317] Overview.

[0318] NeoTCR products can be used alone or for combined treatment. The combination therapy may include applying NeotCR products and applying 1, 2, 3, 4, 5, 6, or 7 or more other treatment agents. In some embodiments, the combination therapy includes the application of Neotcr products and at least one other treatment agent. In some embodiments, the combination therapy includes the application of NeoTCR products and at least two other treatment agents. In some embodiments, the combination therapy includes the application of Neotcr products and at least three other therapeutic agents. In some embodiments, the combination therapy includes the application of Neotcr products and at least four other treatment agents. In some embodiments, the combination therapy includes the application of NeoTCR products and at least five other treatment agents. In some embodiments, the combination therapy includes the application...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Described herein are methods of treating cancer with a precision genome engineered NeoTCR product.

Description

[0001] Cross reference for related applications [0002] This application requires the preferred right of the US temporary patent application sequence number 62 / 912,545 submitted on October 8, 2019. Its content is included in the way of reference and requires its priority. [0003] Serial list [0004] This manual refers to the sequence list (the name file with the name "0875200153sl.txt" submitted by electronic form on October 8, 2020). The .txt file was generated on October 8, 2020 with a size of 1,030 bytes. All content of the serial list is included in this article by reference. Background technique [0005] The clinical correlation of T cell immunity in controlling multiple groups of human cancer has been determined. The clinical activity observed in the approved drugs in immunochemical tests usually depends on the release of pre -existence internal T cell immune response in each cancer patient. The release of an endogenous T cell immune response after treatment with anti-PD1 / ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61P35/00A61P35/04A61K38/20A61K39/00
CPCA61K38/20A61K39/00A61P35/00A61P35/04A61K45/06A61P35/02A61K2039/5156A61K2039/876A61K35/17A61K31/7076C12N5/0636A61K31/675A61K9/0019A61K47/42A61K9/5068C12N2510/00A61K48/005C07K14/7051A61K2300/00A61K39/3955A61K38/2013A61K38/2086A61K39/0011
Inventor 芭芭拉·森尼诺巴米尼·普兰代尔斯蒂芬妮·曼德尔-卡什曼格雷格·D·法恩阿拉蒂·V·拉奥托德·斯托林斯-施米特马克·瓦尔特·弗罗利希亚历克斯·弗兰祖索夫
Owner 派克特制药公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap